<DOC>
	<DOCNO>NCT02194426</DOCNO>
	<brief_summary>This research study look new DARPin base medication , call MP0250 . There evidence preclinical study MP0250 may effective treatment cancer . This first study MP0250 human main purpose test safety tolerability patient cancer . This study also examine drug change remove body look indicator drug may effective cancer . This study test several different dose level study drug determine safety tolerability profile drug .</brief_summary>
	<brief_title>First-in-human Study Investigate Safety , Tolerability Blood Levels Test Drug MP0250 Cancer Patients</brief_title>
	<detailed_description />
	<criteria>1 . Male female ≥ 18 year 2 . Histologically confirm document advanced metastatic solid tumour refractory least 1 prior regimen standard treatment curative therapy available MP0250 reasonable option 3 . Progressive stable disease document radiologically 4 week prior screen 4 . Presence measurable tumour tumour evaluable per RECIST v1.1 5 . ECOG performance status ≤ 1 6 . Life expectancy ≥ 12 week 7 . Adequate haematological function prior first dose , define : Absolute neutrophils count ≥ 1500 cells/μL Haemoglobin ≥ 9 g/dL Platelet count &gt; 100,000/μL Prothrombin time partial thromboplastin time &lt; 1.2 x ULN 8 . Adequate renal function prior first dose , define either Serum creatinine &lt; 1.5 mg/dL Serum creatinine clearance ≥ 50 mL/min/m2 ( CockroftGault equation ) 9 . Adequate hepatic function prior first dose , define Total bilirubin ≤ 1.5 x ULN AST/ALT ≤ 2.5 x ULN , ≤ 5 x ULN know hepatic metastasis Alkaline phosphatase ≤ 2.5 x ULN , ≤ 5 x ULN know hepatic bone metastases 10 . Female patient negative pregnancy test result screen baseline 1 . Female patient pregnant breastfeed 2 . Haematological malignancy secondary malignancy , currently clinically significant require active intervention 3 . Known untreated symptomatic brain metastasis 4 . Predominantly squamous nonsmall cell lung carcinoma 5 . Antitumour treatment within 4 week first infusion MP0250 , chemotherapy , experimental target therapy , biologics , hormonal therapy radiotherapy . The antitumour treatment need long washout period must give within indicated week first infusion MP0250 : i. Nitrosoureas : 6 week ii . Monoclonal antibody : 8 week 6 . Exceptions : follow antitumour treatment allow indicated i. Palliative radiation bone metastases relieve bone pain ii . Standard care treatment bone modify agent ( i.e . bisphosphonates ) , denosumab , maintenance hormonal therapy metastatic prostate breast cancer , hormonereplacement therapy , oral contraceptive 7 . Presence residual toxicity CTCAE Grade ≥ 2 prior antitumour therapy screening . Except meet exclusion criterion , grade 1 toxicity relate previous treatment acceptable time first infusion MP0250 , well Grade 2 alopecia 8 . Exclusion criterion remove 9 . Major surgical procedure , open biopsy significant traumatic injury within 4 week first dose anticipation major surgical procedure course study , core biopsy minor surgical procedure within 1 week first dose 10 . Serious nonhealing wound , active ulcer untreated bone fracture 11 . Proteinuria screen define ≥ 1+ urinalysis dipstick , confirm ≥ 1g 24h urinalysis 12 . Uncontrolled hypertension serious cardiovascular cardiac condition judge investigator 13 . Severe uncontrolled renal insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>